{
    "web_url": "https://www.nytimes.com/1991/10/08/business/court-to-review-mail-order-sales-tax-curb.html",
    "snippet": "In a case with enormous financial implications for the mail-order industry, the Supreme Court agreed today to reconsider one of its own precedents, a 24-year-old decision that has barred states from taxing an estimated $45 billion a year in mail-o...",
    "lead_paragraph": "In a case with enormous financial implications for the mail-order industry, the Supreme Court agreed today to reconsider one of its own precedents, a 24-year-old decision that has barred states from taxing an estimated $45 billion a year in mail-order sales. The 1967 precedent, which has come under sustained attack in recent years from states eager to capture as much as $3 billion a year in lost tax revenue, held that the Constitution bars states from taxing sales made by out-of-state companies that have no physical presence in the state.",
    "abstract": null,
    "print_page": "1",
    "blog": [],
    "source": "The New York Times",
    "multimedia": [],
    "headline": {
        "main": "Court to Review Mail-Order Sales Tax Curb"
    },
    "keywords": [
        {
            "name": "persons",
            "value": "BILZERIAN, PAUL A"
        },
        {
            "name": "glocations",
            "value": "CALIFORNIA"
        },
        {
            "name": "organizations",
            "value": "SUPREME COURT"
        },
        {
            "name": "organizations",
            "value": "GENETICS INSTITUTE INC"
        },
        {
            "name": "organizations",
            "value": "AMGEN INC"
        },
        {
            "name": "subject",
            "value": "INSIDERS INFORMATION"
        },
        {
            "name": "subject",
            "value": "MAIL ORDER COMPANIES"
        },
        {
            "name": "subject",
            "value": "TAXATION"
        },
        {
            "name": "subject",
            "value": "SALES TAX"
        },
        {
            "name": "subject",
            "value": "VIOLATIONS OF SECURITIES AND COMMODITIES REGULATIONS"
        },
        {
            "name": "subject",
            "value": "EPO (RECOMBINANT ERYTHROPOIETIN) (DRUG)"
        },
        {
            "name": "subject",
            "value": "DRUGS (PHARMACEUTICALS)"
        },
        {
            "name": "subject",
            "value": "REAL ESTATE"
        },
        {
            "name": "subject",
            "value": "STOCKS AND BONDS"
        },
        {
            "name": "subject",
            "value": "RETAIL STORES AND TRADE"
        },
        {
            "name": "subject",
            "value": "GENETIC ENGINEERING"
        }
    ],
    "pub_date": "1991-10-08T00:00:00Z",
    "document_type": "article",
    "news_desk": "Financial Desk",
    "section_name": "Health; Business",
    "subsection_name": null,
    "byline": {
        "person": [
            {
                "organization": "",
                "role": "reported",
                "firstname": "Linda",
                "rank": 1,
                "lastname": "GREENHOUSE"
            }
        ],
        "original": "By LINDA GREENHOUSE"
    },
    "type_of_material": "News",
    "_id": "4fd1a4c58eb7c8105d6bd644",
    "word_count": 1303,
    "slideshow_credits": null
}